As Bio­gen hunts for a turn­around CEO, ex­ecs sketch out a hazy look at an un­cer­tain new fu­ture

Once again, Bio­gen’s board of di­rec­tors is look­ing to ex­e­cute a brisk turn­around in or­der to sat­is­fy in­vestors that it has a sol­id foot­ing and a clear road ahead to grow rev­enues again, in­stead of man­ag­ing a shrink­ing rev­enue stream from ag­ing prod­ucts.

Long­time ob­servers have been here be­fore. Jim Mullen was giv­en a sharp push out of the ex­ec­u­tive suite back in 2010, mak­ing way for George Scan­gos and his team to come in and man­age the Tec­fidera launch, which they did with great suc­cess. Michel Vounatsos was pro­mot­ed from com­mer­cial chief a lit­tle more than 5 years ago as the board took the in­sid­er, stay-the-course route to find some­one to man­age the next gen­er­a­tion of the pipeline and prod­uct gen­er­a­tion.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE